Google
Apple
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
PFIZER, INC. |
Market Closed -
Other stock markets
|
|
After market 07:50:56 pm | ||
| 28.79 USD | -1.03% | 28.82 | +0.10% | |
| 06:56am | Lifeon Pharmaceutical Gets Chinese Drug Regulator's Nod to Market Doxazosin Mesylate | MT |
| 12:23am | AbbVie to buy drug developer Cerevel for $8.7 billion | RE |
Financials (USD)
| Sales 2023 * | 59.18B | Sales 2024 * | 63.38B | Capitalization | 163B |
|---|---|---|---|---|---|
| Net income 2023 * | 3.21B | Net income 2024 * | 13.37B | EV / Sales 2023 * | 3,11x |
| Net Debt 2023 * | 21.59B | Net Debt 2024 * | 14.15B | EV / Sales 2024 * | 2,79x |
| P/E ratio 2023 * | 38,4x | P/E ratio 2024 * | 10,8x | Employees | 83,000 |
| Yield 2023 * | 5,79% | Yield 2024 * | 5,81% | Free-Float | 59.02% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
More news
| 1 day | +0.10% | ||
| 1 week | -4.29% | ||
| Current month | -5.51% | ||
| 1 month | -7.67% | ||
| 3 months | -16.24% | ||
| 6 months | -24.97% | ||
| Current year | -43.81% |
1 week
28.30
29.64
1 month
28.3031.30
Current year
28.3051.60
1 year
28.3054.93
3 years
28.3061.71
5 years
27.8861.71
10 years
27.5161.71
| Managers | Title | Age | Since |
|---|---|---|---|
Albert Bourla
CEO | Chief Executive Officer | 61 | 1992 |
David Denton
DFI | Director of Finance/CFO | 58 | 2022 |
Lidia Fonseca
CTO | Chief Tech/Sci/R&D Officer | 54 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 65 | 2020 | |
Ronald Blaylock
BRD | Director/Board Member | 63 | 2017 |
Shantanu Narayen
BRD | Director/Board Member | 59 | 2013 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 14.74% | 323 M€ | -7.50% | - | |
| 9.37% | 26 M€ | +9.53% | - | |
| 6.48% | 3,593 M€ | -4.98% | ||
| 6.26% | 18 M€ | -7.82% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 23-12-06 | 28.79 | -1.03% | 33,410,517 |
| 23-12-05 | 29.09 | -0.65% | 39,853,005 |
| 23-12-04 | 29.28 | +1.28% | 47,410,449 |
| 23-12-01 | 28.91 | -5.12% | 103,624,040 |
| 23-11-30 | 30.47 | +1.30% | 45,356,593 |
Delayed Quote Nyse, December 06, 2023 at 04:00 pm EST
More quotes
Pfizer, Inc. the world's leading pharmaceutical group. Net sales break down by family of products as follows:
- vaccines (52.4%);
- drugs for the treatment of cancer (15.2%);
- cardiovascular, metabolic and analgesic drugs (11.5%);
- injectable, anti-infectives drugs and active pharmaceutical ingredients (9%);
- drugs for inflammatory and immune diseases (5.5%);
- drugs for rare diseases (4.4%);
- other (2%).
At the end of 2021, the group had more than 39 production sites worldwide.
Net sales are distributed geographically as follows: the United States (36.6%), Europe (22.6%) and other (40.8%).
Sector
Pharmaceuticals
Calendar
Trading Rating :
Investor Rating :
ESG Refinitiv :
C+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
28.79USD
Average target price
40.41USD
Spread / Average Target
+40.37%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -43.81% | 163 B $ | |
| +61.07% | 530 B $ | |
| +44.67% | 438 B $ | |
| -11.34% | 377 B $ | |
| -4.79% | 268 B $ | |
| -9.42% | 258 B $ | |
| +1.56% | 200 B $ | |
| -9.70% | 198 B $ | |
| +2.55% | 144 B $ | |
| -4.13% | 117 B $ |
